Advertisement

Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial

Published:November 24, 2016DOI:https://doi.org/10.1016/j.ajog.2016.11.1036

      Background

      Bupropion is used to treat depression during pregnancy. However, its usefulness as a smoking cessation aid for pregnant women is not fully known.

      Objective

      The objective of the study was to evaluate the preliminary efficacy of bupropion sustained release for smoking cessation during pregnancy.

      Study Design

      We conducted a randomized, prospective, double-blind, placebo-controlled, pilot trial. Pregnant women who smoked daily received individualized behavior counseling and were randomly assigned to a 12 week, twice-a-day treatment with 150 mg bupropion sustained release or placebo. The primary study objectives were to determine whether bupropion sustained release reduces nicotine withdrawal symptoms on the quit date and during the treatment period compared with placebo and whether it increases 7 day point prevalence abstinence at the end of the treatment period and at the end of pregnancy.

      Results

      Subjects in the bupropion (n = 30) and placebo (n = 35) groups were comparable in age, smoking history, number of daily smoked cigarettes, and nicotine dependence. After controlling for maternal age and race, bupropion sustained release reduced cigarette cravings (1.5 ± 1.1 vs 2.1 ± 1.2, P = .02) and total nicotine withdrawal symptoms (3.8 ± 4.3 vs 5.4 ± 5.1, P = .028) during the treatment period. Administration of bupropion sustained release reduced tobacco exposure, as determined by levels of carbon monoxide in exhaled air (7.4 ± 6.4 vs 9.1 ± 5.8, P = .053) and concentrations of cotinine in urine (348 ± 384 ng/mL vs 831 ± 727 ng/mL, P = .007) and increased overall abstinence rates during treatment (19% vs 2%, P = .003). However, there was no significant difference in 7 day point prevalence abstinence rates between the 2 groups at the end of medication treatment (17% vs 3%, P = .087) and at the end of pregnancy (10% vs 3%, P = .328).

      Conclusion

      Individual smoking cessation counseling along with the twice-daily use of 150 mg bupropion sustained release increased smoking cessation rates and reduced cravings and total nicotine withdrawal symptoms during the treatment period. However, there was no significant difference in abstinence rates between groups at the end of medication treatment and at the end of pregnancy, likely because of the small sample size. A larger study is needed to confirm these findings and to examine the potential benefit/ risk ratio of bupropion sustained release for smoking cessation during pregnancy.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Patnode C.P.
        • Henderson J.T.
        • Thompson J.H.
        • Senger C.A.
        • Fortmann S.P.
        • Whitlock E.P.
        Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the US Preventive Services Task Force. Evidence synthesis no. 134. AHRQ publication no. 14-05200-EF-1.
        Agency for Healthcare Research and Quality, Rockville (MD)2015
        • Fiore M.C.
        • Jaén C.R.
        • Baker T.B.
        • et al.
        Treating tobacco use and dependence: 2008 update. US Public Health Service Clinical Practice Guideline Executive Summary.
        Respir Care. 2008; 53: 1217-1222
        • Lumley J.
        • Oliver S.S.
        • Chamberlain C.
        • Oakley L.
        Interventions for promoting smoking cessation during pregnancy.
        Cochrane Database Syst Rev. 2004; : CD001055
        • Raupach T.
        • van Schayck C.P.
        Pharmacotherapy for smoking cessation: current advances and research topics.
        CNS Drugs. 2011; 25: 371-382
        • Chan B.
        • Einarson A.
        • Koren G.
        Effectiveness of bupropion for smoking cessation during pregnancy.
        J Addict Dis. 2005; 24: 19-23
        • Stout R.L.
        • Wirtz P.W.
        • Carbonari J.P.
        • Del Boca F.K.
        Ensuring balanced distribution of prognostic factors in treatment outcome research.
        J Stud Alcohol Suppl. 1994; 12: 70-75
        • Rollnick S.
        • Butler C.C.
        • Stott N.
        Helping smokers make decisions: the enhancement of brief intervention for general medical practice.
        Patient Educ Couns. 1997; 31: 191-203
        • Rollnick S.
        • Heather N.
        • Gold R.
        • Hall W.
        Development of a short ‘readiness to change’ questionnaire for use in brief, opportunistic interventions among excessive drinkers.
        Br J Addict. 1992; 87: 743-754
        • Dornelas E.A.
        • Magnavita J.
        • Beazoglou T.
        • et al.
        Efficacy and cost-effectiveness of a clinic-based counseling intervention tested in an ethnically diverse sample of pregnant smokers.
        Patient Educ Couns. 2006; 64: 342-349
        • Berg C.J.
        • Park E.R.
        • Chang Y.
        • Rigotti N.A.
        Is concern about post-cessation weight gain a barrier to smoking cessation among pregnant women?.
        Nicotine Tob Res. 2008; 10: 1159-1163
        • Fucito L.M.
        • Toll B.A.
        • Salovey P.
        • O'Malley S.S.
        Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment.
        Psychol Addict Behav. 2009; 23: 373-379
        • Heatherton T.F.
        • Kozlowski L.T.
        • Frecker R.C.
        • Fagerström K.O.
        The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.
        Br J Addict. 1991; 86: 1119-1127
        • Hughes J.
        • Hatsukami D.K.
        Errors in using tobacco withdrawal scale.
        Tob Control. 1998; 7: 92-93
        • Spitzer R.L.
        • Kroenke K.
        • Williams J.B.
        Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.
        JAMA. 1999; 282: 1737-1744
        • Bailey B.A.
        Using expired air carbon monoxide to determine smoking status during pregnancy: preliminary identification of an appropriately sensitive and specific cut-point.
        Addict Behav. 2013; 38: 2547-2550
        • Higgins S.T.
        • Heil S.H.
        • Badger G.J.
        • et al.
        Biochemical verification of smoking status in pregnant and recently postpartum women.
        Exp Clin Psychopharmacol. 2007; 15: 58-66
        • Aurrekoetxea J.J.
        • Murcia M.
        • Rebagliato M.
        • et al.
        Determinants of self-reported smoking and misclassification during pregnancy, and analysis of optimal cut-off points for urinary cotinine: a cross-sectional study.
        BMJ Open. 2013; 3
        • Stragierowicz J.
        • Mikołajewska K.
        • Zawadzka-Stolarz M.
        • Polańska K.
        • Ligocka D.
        Estimation of cutoff values of cotinine in urine and saliva for pregnant women in Poland.
        Biomed Res Int. 2013; 2013: 386784
      1. Food and Drug Administration. Guidance for industry, bio-analytical method validation. Food and Drug Administration, Center for Drug Evaluation and Research, May 2011. Available at: http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry. Accessed December 29, 2016.

        • Fokina V.M.
        • Wang X.
        • Ahmed M.
        • Oncken C.
        • Hankins G.D.V.
        • Nanovskaya T.N.
        Determination of cotinine in the urine of pregnant patients enrolled in a clinical trial for the use of bupropion sustained release as an aid for smoking cessation.
        Drug and Alcohol Dependence. 2015; 146: e280
        • Petersen G.O.
        • Leite C.E.
        • Chatkin J.M.
        • Thiesen F.V.
        Cotinine as a biomarker of tobacco exposure: development of a HPLC method and comparison of matrices.
        J Sep Sci. 2010; 33: 516-521
        • Wang X.
        • Abdelrahman D.R.
        • Fokina V.M.
        • Hankins G.D.
        • Ahmed M.S.
        • Nanovskaya T.N.
        Metabolism of bupropion by baboon hepatic and placental microsomes.
        Biochem Pharmacol. 2011; 82: 295-303
        • Fokina V.M.
        • Xu M.
        • Rytting E.
        • et al.
        Pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy.
        Drug Metab Dispos. 2016; 44: 1832-1838
        • Oncken C.
        • Campbell W.
        • Chan G.
        • Hatsukami D.
        • Kranzler H.R.
        Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers.
        J Matern Fetal Neonatal Med. 2009; 22: 751-758
        • Hurt R.D.
        • Sachs D.P.
        • Glover E.D.
        • et al.
        A comparison of sustained-release bupropion and placebo for smoking cessation.
        N Engl J Med. 1997; 337: 1195-1202
        • Oncken C.A.
        • Kranzler H.R.
        Pharmacotherapies to enhance smoking cessation during pregnancy.
        Drug Alcohol Rev. 2003; 22: 191-202
        • Croft H.
        • Houser T.L.
        • Jamerson B.D.
        • et al.
        Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.
        Clin Ther. 2002; 24: 662-672
        • Hays J.T.
        • Ebbert J.O.
        Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.
        CNS Drugs. 2003; 17: 71-83
        • Palmsten K.
        • Setoguchi S.
        • Margulis A.V.
        • Patrick A.R.
        • Hernández-Díaz S.
        Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?.
        Am J Epidemiol. 2012; 175: 988-997
        • De Vera M.A.
        • Bérard A.
        Antidepressant use during pregnancy and the risk of pregnancy-induced hypertension.
        Br J Clin Pharmacol. 2012; 74: 362-369
        • Palmsten K.
        • Huybrechts K.F.
        • Michels K.B.
        • et al.
        Antidepressant use and risk for preeclampsia.
        Epidemiology. 2013; 24: 682-691
        • Coleman T.
        • Chamberlain C.
        • Davey M.A.
        • Cooper S.E.
        • Leonardi-Bee J.
        Pharmacological interventions for promoting smoking cessation during pregnancy.
        Cochrane Database Syst Rev. 2015; : CD010078